{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:18:57Z","timestamp":1790684337428,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"suppl_8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,16]]},"DOI":"10.1093\/infdis\/jix135","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T19:37:03Z","timestamp":1490297823000},"page":"S792-S796","source":"Crossref","is-referenced-by-count":26,"title":["Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection"],"prefix":"10.1093","volume":"216","author":[{"given":"Maria","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"key\n\t\t\t\t20171116025727_CIT0001","volume-title":"Hepatitis B","author":"World Health Organization"},{"key":"key\n\t\t\t\t20171116025727_CIT0002","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171116025727_CIT0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025727_CIT0004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","year":"2012","journal-title":"Hepatol Int"},{"key":"key\n\t\t\t\t20171116025727_CIT0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"American Association for the Study of Liver Diseases","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025727_CIT0006","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20171116025727_CIT0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171116025727_CIT0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025727_CIT0009","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171116025727_CIT0010","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20171116025727_CIT0011","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-na\u00efve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety","volume":"106","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171116025727_CIT0012","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","year":"2013","journal-title":"Mol Pharm"},{"key":"key\n\t\t\t\t20171116025727_CIT0013","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171116025727_CIT0014","first-page":"1194A","article-title":"Antiviral activity of tenofovir alafenamide against drug-resistant HBV isolates in vitro","volume":"64","year":"2016","journal-title":"Hepatology (Baltimore)"},{"key":"key\n\t\t\t\t20171116025727_CIT0015","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"GS-US-292-0104\/0111 Study Team","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171116025727_CIT0016","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial","volume":"3","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20171116025727_CIT0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"GS-US-292-0109 team","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171116025727_CIT0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025727_CIT0019","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol"},{"key":"key\n\t\t\t\t20171116025727_CIT0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol"},{"key":"key\n\t\t\t\t20171116025727_CIT0021","first-page":"914A","article-title":"Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B","volume":"64","year":"2016","journal-title":"Hepatology (Baltimore)"},{"key":"key\n\t\t\t\t20171116025727_CIT0022","first-page":"909A","article-title":"No resistance to tenofovir alafenamide detected through 48 weeks of treatment in patients with chronic hepatitis B","volume":"64","year":"2016","journal-title":"Hepatology (Baltimore)"},{"key":"key\n\t\t\t\t20171116025727_CIT0023","first-page":"910A","article-title":"Improved renal laboratory parameters in CHB patients treated with TAF compared with tenofovir disoproxil fumarate (TDF)","volume":"64","year":"2016","journal-title":"Hepatology (Baltimore)"},{"key":"key\n\t\t\t\t20171116025727_CIT0024","first-page":"35A","article-title":"Reduced changes in bone mineral density in CHB patients receiving tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate","volume":"64","year":"2016","journal-title":"Hepatology (Baltimore)"},{"key":"key\n\t\t\t\t20171116025727_CIT0025","first-page":"916A","article-title":"Comparison of markers of bone turnover demonstrates less changes in CHB patients receiving tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF)","volume":"64","journal-title":"Hepatology (Baltimore)"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_8\/S792\/21796956\/jix135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:56:28Z","timestamp":1568937388000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jid\/article\/216\/suppl_8\/S792\/4636134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,15]]},"references-count":25,"journal-issue":{"issue":"suppl_8","published-online":{"date-parts":[[2017,11,16]]},"published-print":{"date-parts":[[2017,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix135","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,15]]},"published":{"date-parts":[[2017,10,15]]}}}